01—Abstract
Summary
Summary of the 8-K filed December 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) filed this Form 8-K on December 3, 2024 under Item 7.01 (Regulation FD Disclosure) to furnish a press release announcing topline results from the Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis.
The study, conducted by Kinevant Sciences, failed to meet its primary endpoint, defined as the proportion of subjects with a Rescue Event during the double-blind period. Secondary endpoints, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the King's Sarcoidosis Questionnaire, also failed to show a treatment benefit consistent with the primary endpoint. As a result, Kinevant will discontinue further development of namilumab for sarcoidosis, and the company states the safety profile remained similar to previous studies.
Kinevant plans to publish the RESOLVE-Lung results to inform future sarcoidosis research. The study enrolled 107 patients in a randomized, double-blind, placebo-controlled design at sites in the U.S. and Europe.
For investors, the filing reports a clinical failure and the end of one program in sarcoidosis, with management emphasizing that the study was well designed and that Roivant will continue pursuing calculated risks in other programs. The filing itself does not quantify any financial impact of this discontinuation.
02—Key points
Key Highlights
- Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis failed to show treatment benefit.
- Namilumab failed to meet the primary endpoint: proportion of subjects with a Rescue Event during the double-blind period.
- Secondary endpoints, including change in percent predicted FVC, corticosteroid tapering success, and King's Sarcoidosis Questionnaire change, showed no treatment benefit consistent with the primary endpoint.
- Further development of namilumab for sarcoidosis will be discontinued by Kinevant.
- Safety profile of namilumab in RESOLVE-Lung remains similar to previous studies.
- The study enrolled 107 patients in a randomized, double-blind, placebo-controlled design at U.S. and European sites.
- Kinevant plans to publish RESOLVE-Lung results to inform future sarcoidosis research; the filing is furnished under Regulation FD and not deemed filed under the Exchange Act.
03—Questions
Frequently Asked Questions
What did the RESOLVE-Lung study test?
The Phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody given once monthly by subcutaneous injection, in patients with chronic active pulmonary sarcoidosis.
Why did the study fail?
Namilumab failed to meet its primary endpoint, the proportion of subjects with a Rescue Event during the double-blind period, and secondary endpoints likewise showed no treatment benefit consistent with the primary result.
Will development of namilumab continue?
No. Kinevant will discontinue further development of namilumab for the treatment of sarcoidosis.
Did namilumab raise any new safety concerns?
The company states the safety profile of namilumab in RESOLVE-Lung remains similar to previous studies.
What does this mean for Roivant's other programs?
The filing does not discuss the impact on other programs. Roivant's CEO stated the company is proud of its successes in other programs this year and will continue taking calculated risks on similar programs, and the press release lists its pipeline including IMVT-1402, batoclimab, brepocitinib, and mosliciguat.
04—Continue